JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

Corvus Pharmaceuticals Inc

Geschlossen

4.71 -1.05

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

4.67

Max

4.72

Schlüsselkennzahlen

By Trading Economics

Einkommen

27M

15M

Angestellte

31

EBITDA

-1.8M

-9.9M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+176.01% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

67M

343M

Vorheriger Eröffnungskurs

5.76

Vorheriger Schlusskurs

4.71

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Corvus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

25. Juli 2025, 17:53 UTC

Wichtige Markttreiber

Genworth Shares Rise On UK Court Ruling That Could Lead to $750 Million Windfall

25. Juli 2025, 15:58 UTC

Ergebnisse
Wichtige Markttreiber

Aon Shares Rise After 2Q Earnings Beat

25. Juli 2025, 15:08 UTC

Wichtige Markttreiber

AST SpaceMobile Shares Slide After Convertible Notes, Stock Offerings

25. Juli 2025, 21:40 UTC

Market Talk

Starbucks' Spending Hikes Are Misdirected -- Market Talk

25. Juli 2025, 21:23 UTC

Market Talk

Honeywell's Growth Seen Holding Up Despite Recent Headwinds -- Market Talk

25. Juli 2025, 20:40 UTC

Ergebnisse

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25. Juli 2025, 20:10 UTC

Ergebnisse

These Stocks Moved the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25. Juli 2025, 19:56 UTC

Ergebnisse

Correction to Why Bargain Hunters Are Flocking to 'Bin Stores' -- Barrons.com on July 20

25. Juli 2025, 19:14 UTC

Market Talk

Oil Futures Post Back-to-Back Weekly Losses -- Market Talk

25. Juli 2025, 19:10 UTC

Market Talk

U.S. Natural Gas Futures Appear to Stabilize -- Market Talk

25. Juli 2025, 19:01 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25. Juli 2025, 18:45 UTC

Market Talk

Gold Ends Down Week on Lower Note -- Market Talk

25. Juli 2025, 18:35 UTC

Akquisitionen, Fusionen, Übernahmen

Sale Could Fetch Around $1B, Sources Say -- WSJ

25. Juli 2025, 18:35 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH in Talks to Sell Marc Jacobs -- WSJ

25. Juli 2025, 18:35 UTC

Akquisitionen, Fusionen, Übernahmen

Suitors for Marc Jacobs Include Authentic, Bluestar Alliance and WHP Global, Sources Say -- WSJ

25. Juli 2025, 18:35 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH Exploring Sale of Fashion Brand Marc Jacobs, Sources Say -- WSJ

25. Juli 2025, 17:38 UTC

Wichtige Markttreiber

Genworth Shares Rise On UK Court Ruling That Could Lead to $750M Windfall

25. Juli 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Extends Decline -- Market Talk

25. Juli 2025, 17:13 UTC

Ergebnisse

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25. Juli 2025, 16:46 UTC

Ergebnisse

Volkswagen Teases Made-in-America Audis, Porsches After $1.5 Billion Tariff Hit -- 2nd Update

25. Juli 2025, 16:45 UTC

Ergebnisse

Apple Earnings Are Next Week. Why This Analyst Says Be Cautious. -- Barrons.com

25. Juli 2025, 16:27 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25. Juli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25. Juli 2025, 16:02 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Berkshire Stock Is Losing Its Buffett Premium. Now Is the Time to Buy. -- Barrons.com

25. Juli 2025, 15:34 UTC

Ergebnisse

Intel's Harsh Reality Nullifies Tariff Boost -- WSJ

25. Juli 2025, 15:06 UTC

Market Talk

Base Metal Prices Fall on Stronger U.S. Dollar -- Market Talk

25. Juli 2025, 15:05 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Comfort Systems, and More -- Barrons.com

25. Juli 2025, 14:45 UTC

Market Talk

Oil Rangebound Amid U.S.-EU Trade Uncertainty -- Market Talk

25. Juli 2025, 14:44 UTC

Market Talk

Gold Futures Set to End Week Lower on Easing Trade War Concerns -- Market Talk

25. Juli 2025, 14:36 UTC

Market Talk
Ergebnisse

Phillips 66 CEO Says California Administration Supports of LA Plant Closure -- Market Talk

Peer-Vergleich

Kursveränderung

Corvus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

176.01% Vorteil

12-Monats-Prognose

Durchschnitt 13 USD  176.01%

Hoch 17 USD

Tief 11 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corvus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

4

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

3.165 / 3.5827Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Weak Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.